Related Experiment Video

Updated: Dec 19, 2025

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans
07:35

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans

Published on: February 4, 2014

11.8K

Population pharmacokinetics of olanzapine in children

Anil R Maharaj1, Huali Wu1, Kanecia O Zimmerman1,2

  • 1Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.

British Journal of Clinical Pharmacology
|June 5, 2020
PubMed

Insights

This study developed a population pharmacokinetic (PopPK) model for olanzapine in children, creating a dosing scheme to achieve similar drug exposure levels as in adolescents and adults. Body weight and postmenstrual age influence olanzapine clearance in pediatric patients.

Area of Science:

  • Pharmacokinetics
  • Pediatric Pharmacology
  • Drug Development

Background:

  • Olanzapine is used in pediatric populations, but dosing requires optimization.
  • Understanding population pharmacokinetics (PopPK) is crucial for safe and effective pediatric drug use.

Purpose of the Study:

  • To evaluate the population pharmacokinetics (PopPK) of olanzapine in children.
  • To develop a model-informed pediatric dosing strategy for olanzapine.

Main Methods:

  • Utilized a nonlinear mixed-effects modeling approach (NONMEM v7.4) with plasma samples from pediatric patients.
  • Developed a one-compartment model with linear elimination, incorporating body weight and postmenstrual age (PMA) as covariates.

Main Results:

  • The final PopPK model identified body weight and PMA as key covariates affecting olanzapine clearance (CL/F).
  • Dosing schemes were developed, differentiating between infants (<6 months or <15 kg) and older children (≥15 kg).

Conclusions:

  • This study presents the first PopPK model for enterally-administered olanzapine in pediatric patients from infancy to adolescence.
  • Body weight and PMA are critical factors in olanzapine's apparent clearance during pediatric development.
Abstract

Keywords:
childrendosingolanzapinepaediatricpopulation pharmacokinetics

More Related Videos

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.4K
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

33.0K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
164
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
189
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
147
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
123
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
171
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
522